Evidence map›Paper›PMID 31201249›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020

Prospective Evaluation of PSMA-Targeted

Steven P Rowe, Scott P Campbell, Margarita Mana-Ay, Zsolt Szabo, Mohamad E Allaf, Kenneth J Pienta, Martin G Pomper, Ashley E Ross, Michael A Gorin

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07455097 (COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER), which is not on this map. Cited by 39 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07455097 active not recruitingnot on this mapstarted 2026, after this paper: background citation

COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) - A Multicentre Retrospective Analysis in the European Prostate Cancer Centres of Excellence for Prostate Cancer (EPCCE)

TypeobservationalSponsorHeinrich-Heine University, DuesseldorfRan2026 to 2026Enrolled600ConditionsIntermediate-risk Prostate Cancer, High-risk Prostate CancerArmsPSMA-11
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. The Diagnostic Role ofFrontiers in oncology · 2021
    Pooled it
  4. Pooled it
  5. The performance ofAsian journal of andrology
    Pooled it
  6. Radiology · 2022
    Trial
  7. Trial
  8. Patterns of disease detection using [European journal of nuclear medicine and molecular imaging · 2021
    Trial
  9. Diagnostic Performance ofClinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Changes in Management AfterJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  17. Review
  18. Article
  19. Pathological predictors ofBJU international · 2022
    Article
  20. Clinical experience withEuropean journal of hybrid imaging · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Steven P RoweRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland srowe8@jhmi.edu.
Scott P CampbellJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Margarita Mana-AyJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Zsolt SzaboRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Mohamad E AllafJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Kenneth J PientaJames Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Martin G PomperRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ashley E RossTexas Urology Specialists, Mary Crowley Cancer Research Center, Dallas, Texas.
Michael A GorinRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our purpose is to provide the results of a prospective study evaluating prostate-specific membrane antigen-targeted

Indexed as

AdenocarcinomaAgedFluorodeoxyglucose F18HumansImage Processing, Computer-AssistedLysineMaleMiddle AgedNeoplasm MetastasisPilot ProjectsPositron Emission Tomography Computed TomographyPostoperative PeriodProspective StudiesProstatectomyProstate-Specific AntigenProstatic Neoplasms2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acidFluorodeoxyglucose F18LysineProstate-Specific AntigenProteasome Endopeptidase ComplexPSMA1 protein, humanUreabiochemical persistencebiochemical recurrencegenitourinaryoncologyPET/CTprostate-specific membrane antigen

Identifiers

PMID31201249
PMCPMC6954467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.